常染色体显性多囊肾病的临床表现及其诊治进展
Clinical Manifestations, Diagnosis and Treatment Progress of Autosomal Dominant Polycystic Kidney Disease
DOI: 10.12677/ACM.2022.124498, PDF,    科研立项经费支持
作者: 董辉辉, 李新建*：济宁医学院临床医学院，山东 济宁；徐 璐：济宁医学院附属医院血液净化科，山东 济宁
关键词: 多囊肾；ADPKD；临床表现；诊治；Polycystic Kidney Disease； ADPKD； Clinical Manifestations； Diagnosis and Treatment
摘要: 常染色体显性遗传多囊肾病(ADPKD)是最常见的遗传性肾病之一，是终末期肾病(ESRD)的一大病因。其发病主要是由于PKD基因突变引起的。常见临床表现为肾功异常、高血压、囊肿感染、出血、尿路感染、疼痛等。多囊肾病的临床表现不一，确诊后需要进一步筛查有无囊肿形成、体积增大引起的症状及其他系统性表现，以便更好地治疗疾病和提高生存质量。很多人认为ADPKD只是单纯地局限于肾脏表现，其实ADPKD是一种可累及泌尿、消化、神经、生殖等多个系统的系统性疾病。本文将对ADPKD的典型临床表现及其诊治做一个综述，以期能够为其早期诊断、全面治疗、减少并发症提供参考。
Abstract: As one of the most common hereditary nephropathies, autosomal dominant polycystic kidney disease (ADPKD) is a major pathogeny for end-stage renal disease (ESRD). ADPKD is mainly caused by polycystic kidney disease (PKD) mutation. Common clinical manifestations may include abnormal renal function, hypertension, cyst infection, hemorrhage, urinary tract infection, pain, etc. As ADPKD clinical manifestations vary greatly, it is necessary to further detect if there are symptoms caused by the formation or volume increase of cyst, or any other systematic manifesta-tions, in order to better control the disease and improve life quality of the patient. Many people believe that ADPKD merely has renal manifestations, but it actually is a systemic disease that can impact multiple systems including urinary system, digestive system, nervous system, and repro-ductive system. This paper reviews the typical clinical manifestations and corresponding diagno-sis/treatment of ADPKD, with the goal of providing reference for early diagnosis, comprehensive treatment, and complication alleviation.
文章引用：董辉辉, 徐璐, 李新建. 常染色体显性多囊肾病的临床表现及其诊治进展[J]. 临床医学进展, 2022, 12(4): 3440-3447. https://doi.org/10.12677/ACM.2022.124498

参考文献

[1] Bae, K.T., Zhou, W., Shen, C., et al. (2019) Growth Pattern of Kidney Cyst Number and Volume in Autosomal Domi-nant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology, 14, 823-833. [Google Scholar] [CrossRef] 
[2] Grantham, J.J., Mulamalla, S. and Swenson-Fields, K.I. (2011) Why Kidneys Fail in Autosomal Dominant Polycystic Kidney Disease. Nature Reviews Nephrology, 7, 556-566. [Google Scholar] [CrossRef] [PubMed]
[3] Edwards, M.E., Chebib, F T, Irazabal M V, et al. (2018) Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology, 13, 1153-1161. [Google Scholar] [CrossRef] 
[4] Rysz, J., Gluba-Brzózka, A., Franczyk, B., et al. (2016) Combination Drug versus Monotherapy for the Treatment of Autosomal Dominant Polycystic Kidney Disease. Expert Opinion on Pharmacotherapy, 17, 2049-2056. [Google Scholar] [CrossRef] [PubMed]
[5] Tyson, M.D. and Humphreys, M.R. (2014) Urological Ap-plications of Natural Orifice Transluminal Endoscopic Surgery (NOTES). Nature Reviews Urology, 11, 324-332. [Google Scholar] [CrossRef] [PubMed]
[6] Walz, G., Budde, K., Mannaa, M., et al. (2010) Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. The New England Journal of Medicine, 363, 830-840. [Google Scholar] [CrossRef] 
[7] Abbott, K.C. and Agodoa, L.Y. (2002) Polycystic Kidney Disease at End-Stage Renal Disease in the United States: Patient Characteristics and Survival. Clinical Nephrology, 57, 208-214. [Google Scholar] [CrossRef] 
[8] Jung, Y., Irazabal, M.V., Chebib, F.T., et al. (2015) Volume Regression of Native Polycystic Kidneys after Renal Transplantation. Nephrology Dialysis Transplantation, 31, 73-79. [Google Scholar] [CrossRef] [PubMed]
[9] Lotan, Y., Daudon, M., Bruyère, F., et al. (2013) Impact of Fluid Intake in the Prevention of Urinary System Diseases: A Brief Review. Current Opinion in Nephrology & Hypertension, 22, S1-S10. [Google Scholar] [CrossRef] 
[10] Casteleijn, N.F., Messchendorp, A.L., Bae, K.T., et al. (2016) Polyuria Due to Vasopressin V2 Receptor Antagonism Is Not Associated with Increased Ureter Diameter in ADPKD Patients. Clinical & Experimental Nephrology, 21, 375-382. [Google Scholar] [CrossRef] [PubMed]
[11] Carlsson, S., Wiklund, N.P., Engstrand, L., et al. (2001) Effects of pH, Nitrite, and Ascorbic Acid on Nonenzymatic Nitric Oxide Generation and Bacterial Growth in Urine. Nitric Oxide, 5, 580-586. [Google Scholar] [CrossRef] [PubMed]
[12] Flo, T.H., Smith, K.D., Sato, S., et al. (2004) Lipocalin 2 Mediates an Innate Immune Response to Bacterial Infection by Sequestrating Iron. Nature, 432, 917-921. [Google Scholar] [CrossRef] [PubMed]
[13] Casteleijn, N.F., Visser, F.W., Drenth, J.P.H., et al. (2014) A Stepwise Approach for Effective Management of Chronic Pain in Autosomal-Dominant Polycystic Kidney Disease. Nephrology Dialysis Transplantation, 29, iv142-iv153. [Google Scholar] [CrossRef] [PubMed]
[14] Torres, V.E., Chapman, A.B., De Vuyst, O., et al. (2012) Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 367, 2407-2418. [Google Scholar] [CrossRef] 
[15] Santoro, D., Satta, E., Messina, S., et al. (2013) Pain in End-Stage Renal Disease: A Frequent and Neglected Clinical Problem. Clinical Nephrology, 79, 2-11. [Google Scholar] [CrossRef] 
[16] Allan, L., Hays, H., Jensen, N.H., et al. (2001) Randomised Crossover Trial of Transdermal Fentanyl and Sustained Release Oral Morphine for Treating Chronic Non-Cancer Pain. British Medical Journal, 322, Article No. 1154. [Google Scholar] [CrossRef] [PubMed]
[17] Tellman, M.W., et al. (2015) Management of Pain in Autosomal Dominant Polycystic Kidney Disease and Anatomy of Renal Innervation. Journal of Urology, 193, 1470-1478. [Google Scholar] [CrossRef] [PubMed]
[18] Hall, H. and Leach, A. (1999) Paravertebral Block in the Man-agement of Liver Capsule Pain after Blunt Trauma. British Journal of Anaesthesia, 83, 819-821. [Google Scholar] [CrossRef] [PubMed]
[19] Peces, R., et al. (2012) Medical Therapy with Tranexamic Acid in Au-tosomal Dominant Polycystic Kidney Disease Patients with Severe Haematuria. Nefrología: Publicación Oficial De La Sociedad Espaola Nefrologia, 32, 160-165.
[20] Suwabe, T., Ubara, Y., Sumida, K., et al. (2012) Clinical Features of Cyst Infection and Hemorrhage in ADPKD: New Diagnostic Criteria. Clinical and Experimental Nephrology, 16, 892-902. [Google Scholar] [CrossRef] [PubMed]
[21] Qu, M.L., Ramirez-Giraldo, J.C., Leng, S., et al. (2011) Dual-Energy Dual-Source CT with Additional Spectral Filtration Can Improve the Differentiation of Non-Uric Acid Renal Stones: An Ex Vivo Phantom Study. American Journal of Roentgenology, 196, 1279-1287. [Google Scholar] [CrossRef] 
[22] Liu, Y., Li, Y., Li, N., et al. (2012) Flexible Ureteroscopy and Holmium Laser Lithotripsy for Treatment of Upper Urinary Tract Calculi in Patients with Autosomal Dominant Polycystic Kidney Disease. Urological Research, 40, 87-91. [Google Scholar] [CrossRef] [PubMed]
[23] Umbreit, E.C., Childs, M.A., Patterson, D.E., et al. (2010) Percutaneous Nephrolithotomy for Large or Multiple Upper Tract Calculi and Autosomal Dominant Polycystic Kidney Disease. Journal of Urology, 183, 183-187. [Google Scholar] [CrossRef] [PubMed]
[24] Krishnan, N. and Perazella, M.A. (2017) The Role of PET Scan-ning in the Evaluation of Patients with Kidney Disease. Advances in Chronic Kidney Disease, 24, 154-161. [Google Scholar] [CrossRef] [PubMed]
[25] Suwabe, T., Araoka, H., Ubara, Y., et al. (2015) Cyst Infection in Autosomal Dominant Polycystic Kidney Disease: Causative Microorganisms and Susceptibility to Lipid-Soluble Antibiotics. European Journal of Clinical Microbiology & Infectious Diseases, 34, 1369-1379. [Google Scholar] [CrossRef] [PubMed]
[26] Harris, P.C. and Torres, V.E. (2006) Polycystic Kidney Disease, Autosomal Dominant. Springer, Berlin.
[27] Sallée, M., et al. (2009) Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology, 4, 1183-1189. [Google Scholar] [CrossRef] 
[28] Hogan, M.C., Abebe, K., Torres, V.E., (2015) Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. Clinical Gastroenterology and Hepatology, 13, 155-164.E6. [Google Scholar] [CrossRef] [PubMed]
[29] Chauveau, D., Fakhouri, F. and Grünfeld, J.P. (2000) Liver In-volvement in Autosomal-Dominant Polycystic Kidney Disease: Therapeutic Dilemma. Journal of the American Society of Nephrology, 11, 1767-1775. [Google Scholar] [CrossRef] 
[30] Pei, Y. and Watnick, T. (2010) Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 17, 115-117. [Google Scholar] [CrossRef] [PubMed]
[31] Drenth, J., Chrispijn, M., Nagorney, D.M., et al. (2010) Medical and Surgical Treatment Options for Polycystic Liver Disease. Hepatology, 52, 2223-2230. [Google Scholar] [CrossRef] [PubMed]
[32] Hogan, M.C., Masyuk, T., Bergstralh, E., et al. (2015) Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients with Severe Polycystic Liver Disease. Mayo Clinic Proceedings, 90, 1030-1037. [Google Scholar] [CrossRef] [PubMed]
[33] Schrier, R.W., Johnson, A.M., Mcfann, K., et al. (2003) The Role of Parental Hypertension in the Frequency and Age of Diagnosis of Hypertension in Offspring with Autoso-mal-Dominant Polycystic Kidney Disease. Kidney International, 64, 1792-1799. [Google Scholar] [CrossRef] [PubMed]
[34] Ritchie, L.D., Campbell, N.C. and Murchie, P. (2011) New NICE Guidelines for Hypertension. British Medical Journal, 343, d5644. [Google Scholar] [CrossRef] [PubMed]
[35] Chapman, A.B., Guay-Woodford, L.M., Grantham, J.J., et al. (2003) Renal Structure in Early Autosomal-Dominant Polycystic Kidney Disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney International, 64, 1035-1045. [Google Scholar] [CrossRef] [PubMed]
[36] Lumiaho, A., Pihlajamäki, J., Hartikainen, J., et al. (2003) Insulin Resistance Is Related to Left Ventricular Hypertrophy in Patients with Polycystic Kidney Disease Type 1. American Journal of Kidney Diseases, 41, 1219-1224. [Google Scholar] [CrossRef] 
[37] Ecder, T., Edelstein, C.L., Fick-Brosnahan, G.M., et al. (2000) Progress in Blood Pressure Control in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 36, 266-271. [Google Scholar] [CrossRef] [PubMed]
[38] Raoul, Z., Roudolf, P., Birgit, S., et al. (2008) Renal and Cardiac Effects of Antihypertensive Treatment with Ramipril vs Metoprolol in Autosomal Dominant Polycystic Kidney Disease. Nephrology Dialysis Transplantation, 23, 431-433. [Google Scholar] [CrossRef] [PubMed]
[39] Helal, I., Al-Rowaie, F., Abderrahim, E., et al. (2017) Update on Path-ogenesis, Management, and Treatment of Hypertension in Autosomal Dominant Polycystic Kidney Disease. Saudi Journal of Kidney Diseases and Transplantation, 28, 253-260. [Google Scholar] [CrossRef] [PubMed]
[40] Pirson, Y., Chauveau, D. and Torres, V. (2002) Management of Cerebral Aneurysms in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology, 13, 269-276. [Google Scholar] [CrossRef] 
[41] Belz, M.M., Hughes, R.L., Kaehny, W.D., et al. (2001) Familial Clustering of Ruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 38, 770-776. [Google Scholar] [CrossRef] [PubMed]
[42] Albrecht, W., Rinkel, G., Wermer, M., et al. (2006) Yield of Short-Term Follow-Up CT/MR Angiography for Small Aneurysms Detected at Screening. Stroke, 37, 414-418. [Google Scholar] [CrossRef] 
[43] Gieteling, E.W. and Rinkel, G. (2003) Characteristics of Intracranial Aneurysms and Subarachnoid Haemorrhage in Patients with Polycystic Kidney Disease. Journal of Neurology, 250, 418-423. [Google Scholar] [CrossRef] [PubMed]
[44] Chebib, F.T. and Torres, V.E. (2016) Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. American Journal of Kidney Diseases, 67, 792-810. [Google Scholar] [CrossRef] [PubMed]

为你推荐